Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council

Ezhov, Marat; Кухарчук, В. В.; Сергиенко, И. В.; Ахмеджанов, Н. М.; Воевода, М. И.; Gurevich, V. S.; Кашталап, В. В.; Константинов, В. О.; Skibitsky, V. V.; Шапошник, И. И.

doi:10.20996/1819-6446-2021-02-02

Racionalʹnaâ farmakoterapiâ v kardiologii

2021

DOI: 10.20996/1819-6446-2021-02-02

|View full text |Cite

Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council

Marat Ezhov¹,

В. В. Кухарчук²,

И. В. Сергиенко³

et al.

Abstract: The meeting of the expert council of cardiologists-lipidologists, organized with the support of Novartis and dedicated to the discussion of the existing system of medical care for patients with familial hypercholesterolemia / mixed dyslipidemia, the modern evidence base for lipid-lowering therapy and the practical value of the strategy of early combined lipid-lowering therapy for doctors and these categories of patients was held in Moscow on November 11, 2020.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Кашталап

2022

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary prevention, the adherence of patients to the lipid-lowering therapy remains low. Fixed-dose combinations (Lipertans) based on antihypertensive (amlodipine, perindopril) and lipid-lowering drugs (atorvastatin) can significantly increase the effectiveness of therapy.

show abstract

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Кашталап

2022

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

show abstract

Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage

Larina,

Mironova,

Larin

et al. 2023

Kardiologiia

View full text Add to dashboard Cite

Aim To evaluate the frequency and structure of lipid-lowering therapy and of achieving the goal of low-density lipoprotein cholesterol (LDL-C) in patients with very high cardiovascular risk (CVR) who were monitored at the outpatient stage. Material and methods A retrospective snapshot analysis was performed by continuous sampling method for 136 medical records of outpatient patients (71 men, 65 women) aged 42 to 91 years [median, 68 years; 25th and 75th percentiles (59; 78)].Results 134 (98,53 %) patients took statins; 8 (5.88 %) patients took a combination of statin and ezetimibe; 2 (1.47 %) patients took proprotein convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9): 2 (1.47 %) patients took evolocumab and 1 (0.74%) of 2 PCSK9-treated patients took a combination of PCSK9 inhibitor and statin. Atorvastatin at a dose of 20 (20; 40) mg as recommended at the hospital was the most frequently prescribed statin. 5 (3.68%) patients achieved the goal LDL-C of ≤1.4 mmol/l.Conclusion Statins prevail in the structure of lipid-lowering therapy in patients with very high CVR. The frequency of combination therapy (statin/ezetimibe, 5.88%; PCSK9 inhibitor/statin, 0.74%) and PCSK9 inhibitors was noted to be low. Only 3.68% of patients achieved the goal LDL-C during the lipid-lowering treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council

Cited by 2 publications

References 7 publications

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage

Contact Info

Product

Resources

About